glp-1 and type 1 diabetes receptor agonists are increasingly used to treat 2 obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal GLP-1 Drugs and Type 1

Maintaining adequate vitamin D year-round through blood work to assess levels and supplementation when needed can therefore be relevant to hormonal health

Still some questions In the past decade, GLP-1 drugs have revolutionized weight loss and diabetes treatment

Clem B, Telang S, Clem A, et al

Landmark clinical trials show GLP-1 users lose 15-22% of body weight over 68 weeks, compared to 2-3% with lifestyle changes alone

The clinical rationale for obesity treatment extends beyond cosmetic benefit to meaningful cardiovascular risk reduction: Wegovy's label now includes cardiovascular risk reduction in overweight adults, fundamentally altering the value proposition for payers [1]

We have offices in Murrieta and Palm Desert, respectively, where we can answer your questions